The Patient Journey Through a Clinical Trial: What to Expect
What does it actually look like to participate in a clinical trial from start to finish? The journey from finding a trial to completing the last follow-up visit can take months or years. Along the way, participants move through screening, informed consent, randomization, treatment schedules, monitoring visits, and long-term follow-up. Understanding that journey helps patients know what to expect, and it helps researchers design trials that are easier for people to live through.
The Clarity Clinical Solutions video on the patient journey breaks the process into six phases: finding and evaluating the trial, the screening visit, informed consent, enrollment and randomization, the treatment period, and post-treatment follow-up. Each phase has its own purpose, timeline, and demands on the participant.
Finding a trial and deciding to pursue it
Before a patient ever sets foot in a clinic, they have to find the trial and decide whether to pursue it. That usually starts with searching registries like ClinicalTrials.gov, the U.S. government database that lists trials from around the world, along with talking to their doctor and learning about the trial's purpose and requirements. Patients review the eligibility criteria, consider the time commitment, and think about logistics like travel and time off work.
This is the decision-making phase, and the video calls it the most important step in the journey. Patients who understand what participation involves before they agree to it are more likely to complete the trial and have a positive experience.
The screening visit
The screening visit is the first formal step. The study team reviews the patient's medical history, performs a physical exam, and runs laboratory tests to confirm eligibility. This visit is more comprehensive than a typical doctor's appointment. It may include an ECG, imaging, blood work, and questionnaires. The screening visit is also the patient's chance to meet the study team, ask questions, and decide whether the trial feels right for them. Screening can take two to four hours and may require multiple appointments.
Informed consent: a conversation, not just a form
If the patient qualifies, the next step is informed consent. This is not simply signing a form. It is a detailed conversation about the trial's purpose, procedures, risks, benefits, and alternatives. U.S. regulations require that consent be sought under circumstances that give the person enough time to decide and that minimize the possibility of coercion or undue influence, and the required elements of consent include the purpose of the research, what will happen, foreseeable risks, possible benefits, and the fact that participation is voluntary (45 CFR 46.116).
Good consent processes often include "teach-back," where the patient explains the trial in their own words to confirm understanding. The video advises patients to take the consent form home and discuss it with family before signing. The right to withdraw at any time is part of that agreement, and withdrawing does not affect a patient's access to regular medical care.
Enrollment and randomization
Once consent is signed, the patient is enrolled and randomly assigned to a treatment group. Randomization means the patient does not choose which treatment they receive; the assignment happens by chance. Participants may receive the experimental drug, the standard treatment, a placebo, or different doses. ClinicalTrials.gov explains randomization as the process of assigning participants to treatment groups by chance rather than by choice, so that the groups are comparable. Neither the patient nor their doctor may know which group they are in, which is called blinding. The study team explains this before randomization happens, but many patients still find the concept confusing.
The treatment period
The treatment period is the core of the trial. Patients take the study medication or receive the experimental intervention on a schedule. Visits happen at regular intervals, weekly, monthly, or quarterly depending on the trial design. At each visit, the study team checks vital signs, reviews side effects, collects blood samples, and administers questionnaires. Patients also fit the trial into daily life: taking medication on schedule, completing diaries, and attending appointments. This phase can last weeks or years.
Monitoring during treatment is intensive. The study team reviews vital signs, lab results, side effects, and any changes in health at every visit. Patient safety is the top priority. If concerning side effects appear, the team can adjust doses, pause treatment, or withdraw the patient. Patients report how they feel in person and through symptom diaries, and electronic patient-reported outcome tools on tablets or smartphones have made this easier, though the frequency of monitoring can still feel overwhelming.
Managing side effects
Managing side effects is a key part of the treatment period. The study team provides guidance on what to expect and how to handle common side effects. Patients are told to report any new symptoms right away, not just at scheduled visits. Serious side effects are reported to the sponsor and regulators within strict timelines. The balance between reporting everything and not becoming anxious about every minor symptom is a real challenge, and the video stresses that good communication with the study team is essential.
How a trial can end
A trial can end in several ways. The ideal outcome is that the patient completes the full treatment period and all follow-up visits. But a patient may withdraw early because of side effects, burden, or personal reasons. The sponsor may stop the trial early if results are overwhelmingly positive or negative. If a patient withdraws, the team may ask permission to continue collecting safety data. Withdrawal is always the patient's right, and it does not affect their access to regular medical care.
Follow-up after treatment
Most trials include a follow-up phase after treatment ends. Patients continue to be monitored, sometimes for months or years, to track long-term safety and how well the treatment effect lasts. At the end of the trial, patients learn which treatment group they were in if the trial was blinded. They may be offered continued access to the experimental treatment through an open-label extension, where everyone receives the study drug. Results are published, and participants have the right to know the overall findings. The relationship with the study team ends, and patients return to their regular doctor for ongoing care.
Designing trials around the patient
The video draws three lessons from the journey. First, the phases are predictable: finding, screening, consenting, treatment, monitoring, and follow-up. Knowing what to expect at each stage reduces anxiety and improves retention. Second, the screening and consent phases matter most because they set expectations and build trust. Take the time to ask questions and involve family in the decision. Third, researchers should design each phase with the patient experience in mind: shorter visits, fewer procedures, clear communication, and respect for the participant's time and comfort.
The bottom line
The patient journey through a clinical trial is a structured path from finding a trial, through screening and consent, to active treatment and long-term follow-up. Each phase has its own purpose, timeline, and challenges. For patients, understanding the journey before it begins reduces anxiety and supports informed decisions. For researchers, designing each phase with the patient in mind improves recruitment, retention, and the quality of the data. The best trials are the ones where the patient journey is designed as carefully as the science.
This article is based on the Clarity Clinical Solutions video "The Patient Journey Through a Clinical Trial." Watch it here: The Patient Journey Through a Clinical Trial
References
- Clarity Clinical Solutions — The Patient Journey Through a Clinical Trial (video). https://www.youtube.com/watch?v=5HdMnLVl1Rk
- U.S. Department of Health and Human Services — 45 CFR 46.116, the Common Rule requirements for informed consent, including the required elements and voluntary participation. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/section-46.116
- ClinicalTrials.gov — Learn About Studies, including how randomization assigns participants to treatment groups by chance. https://clinicaltrials.gov/learn-about-studies
- ClinicalTrials.gov — Main search portal for trials registered in the United States and abroad. https://clinicaltrials.gov/